Highlights from April 9–10: International Scientific Advisory Board & SIRIC Montpellier Cancer Annual Meeting
Priority Session – Latest advances in imaging andtargeted radionuclide therapy Priority Session – Prof. Kevin Prise (Queen’s University Belfast, Ireland): New strategies for targeted alpha therapies in prostate cancer Priority Session – Dr. Timothée David (IRCM, France): In situ vaccine induced by intermediate dose of targeted radionuclide therapy Panacea Session – Cachexia and Cancer Panacea
